▶️▶️Check out this new paper on CLL pts with high risk features treated with Acala-based regimens #CLL #lymsm #acalabrutinib

Acalabrutinib-based regimens in frontline or relapsed/refractory higher-risk CLL: Pooled analysis of 5 clinical trials ashpublications.org/bloodadvances/…

New #OpenAccess study suggest that neoadjuvant platinum-based ICI-chemo. for those with early-stage #NSCLC is associated with improvements in 2-year EFS and pCR 🫁

See the full study in JAMA Network Open by Giuseppe Banna, Mona Hassan, Alfredo Addeo MD & colleagues ⬇️

jamanetwork.com/journals/jaman…

1/ The long-awaited OS results from #KEYNOTE -564 are out NEJM! The 1st phase 3 trial to demonstrate a survival benefit for adjuvant treatment in #RCC .

nejm.org/doi/full/10.10…

Share your anonymous patient case and hear advice from fellow experts at our upcoming roundtable on the clinical implications of HER2 in lung, GI and GYNE cancers.

👩‍⚕️🧑‍⚕️: Ilaria Colombo, Florian Lordick and Hochmair Maximilian.

Submit your case below ⬇️

The FDA Oncology has approved alectinib for adjuvant treatment following tumor resection in those with #ALK -positive #NSCLC 🫁

This approval comes based on the phase 3 ALINA study.

See the full press release ⬇️

Adjuvant pembrolizumab shows a significant and clinically meaningful OS benefit in intermediate and high risk clear cell renal cancer for the 1st time (KN564). This further tips the balance towards giving adjuvant pembro in this setting NEJM Toni Choueiri, MD nejm.org/doi/full/10.10…

Meta-analysis of neoadjuv chemoimmunotherapy in #NSCLC :
1. 3 cycles suffice based on pCR, with adjuvant immunotherapy not enhancing EFS.
2. Kudos to JAMA Network Open team, esp. Sara, for elevating paper quality & reviewers' feedback.
3. Special shoutout to the amazing team!

Discover essential insights that are shaping the current approach to HER2+ lung, gastrointestinal, and gynecological cancers with Ilaria Colombo at her upcoming roundtable with Florian Lordick and Hochmair Maximilian!

⏰ 30th April at 5PM CEST

Tune in for free ⬇️

Don't miss the new ESMO - Eur. Oncology living guideline on non-oncogene-addicted metastatic #NSCLC by Lizza Hendriks, Martin Reck & colleagues!

See the up-to-date treatment algorithms and guidelines ⬇️

New research from Maxime Borgeaud, Timothée Olivier, MD, Alfredo Addeo MD & colleagues finds that 2nd generation #TKI afatinib demonstrates efficacy for G719X, S768I, E709X and L747X mutations, as well as for compound uncommon mutations in #NSCLC 🫁

See the open access article in JTO & JTO CRR ⬇️

Share your anonymous patient case and hear advice from fellow experts at our upcoming roundtable on the clinical implications of HER2 in lung, GI and GYNE cancers.

👩‍⚕️🧑‍⚕️: Ilaria Colombo, Florian Lordick and Hochmair Maximilian.

Submit your case below ⬇️

See the updated ASCO living guideline in Journal of Clinical Oncology which provides expert insights into common clinical scenarios encountered when caring for those with advanced #NSCLC 🫁

#OpenAccess article by Dwight Owen, Narjust Florez, MD, FASCO, Erin Schenk, MD, PhD, Jyoti D Patel and colleagues ⬇️

Check out the agenda for our roundtable on #HER2 + tumors with Ilaria Colombo as our host, along with Florian Lordick and Hochmair Maximilian, which will feature the latest clinical implications across lung, GI, and GYNE cancers.

⏰ 30th April at 5PM CEST

Register and join for free ⬇️

Don't miss the ASCO Educational Book on novel treatment strategies for those with #EGFR -mutant #NSCLC across all stages 🫁

#OpenAccess book by Stephanie Saw, Xiuning Le MD PhD, Lizza Hendriks and Jordi Remon ⬇️

Alectinib in Resected ALK-Positive Non–Small-Cell Lung Cancer | New England Journal of Medicine nejm.org/doi/full/10.10…

#lungcancer is the #1 cause of #cancer related deaths worldwide 🌏.
➡️ But did you know that #Lungcancer in Never Smokers (LCINS) is the 5th most common cause of #cancer related deaths 🌏?
Fantastic talk by Elaine Shum from NYU Langone Health today at #AACR24 . AACR OncoAlert

Discover essential insights that are shaping the current approach to HER2+ lung, gastrointestinal, and gynecological cancers with Ilaria Colombo at her upcoming roundtable with Florian Lordick and Hochmair Maximilian!

⏰ 30th April at 5PM CEST

Tune in for free ⬇️

New global cancer statistics for 2022 are now online at CA: A Cancer Journal for Clinicians from American Cancer Society & IARC 🌎

Close to 20 million new cancer cases occurred in 2022, & they are predicted to reach 35 million by 2050.

Full article by Freddie Bray, Ahmedin Jemal & colleagues ⬇️

New data from EV302 Enfortumab Vedotin & pembrolizumab for upper tract disease (~25% of pts). UTUC has distinct biological features including more FGFR alterations. PFS & OS HR of 0.50 & 0.53 respectively in the subset is in line with the whole population (0.45 and 0.47) #EAU24

What is the role of the TME in lung cancer evolution? We are excited to share our new TRACERx paper “Spatial Architecture of Myeloid and T Cells Orchestrates Immune Evasion and Clinical Outcome in Lung Cancer” at #AACR24 , out in Cancer Discovery today rb.gy/q484j9 Tweetorial👇